The agreement with "CSIR-National Chemical Laboratory and Department of Science and Technology (DST) is for conducting research on a continuous purification process development of a biosimilar monoclonal antibody therapeutic," Lupin said in a BSE filing.
Lupin Senior Vice President and Head - R&D, Biotechnology Rustom Mody said: "Biotech is one of Lupins key growth drivers and we are committed to advancing our biotech R&D capabilities through strategic partnerships."
The collaboration with a premier institution like CSIR is an exemplary industry-academia collaboration that can further the development and commercialisation of biologics and biosimilars for a better and more affordable healthcare to customers across the globe, he added.
Shares of Lupin today closed at Rs 771.30 per scrip on BSE, up 1.41 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)